FDA Approves Updated Covid-19 Vaccines Targeting XFG Variant

1-Minute Brief

The updated vaccines are intended to address the dominant XFG variant and are approved for specific high-risk groups.

Key Facts

• The US Food and Drug Administration approved updated Covid-19 vaccines on Thursday.
• The vaccines target the dominant XFG variant, following an advisory panel's recommendation.
• The updated shots are approved for people 65 and older, and for younger people with underlying conditions.
• Moderna, Novavax-Sanofi, and Pfizer-BioNTech's vaccines were included in the approval.
• Manufacturers can now begin shipping doses to pharmacies and doctors’ offices across the country.

What Happened

The FDA approved updated Covid-19 vaccines from Moderna, Novavax-Sanofi, and Pfizer-BioNTech, targeting the XFG variant and allowing distribution to begin.

Why It Matters

The approval aims to provide protection for those most at risk from the current dominant Covid-19 variant, potentially reducing severe illness in vulnerable populations.

What's Next

Distribution of the updated vaccines will begin, but questions remain about insurance coverage and access for groups outside the approved categories.